Drugs / AZD3427
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06611423 | Oct 2024 → Aug 2025 | impaired renal function disease, systolic heart failure | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT04890548 | Nov 2021 → Aug 2022 | heart failure | AstraZeneca | Withdrawn | No outcome recorded |
| Phase 1 | NCT04630067 | Nov 2020 → Sep 2022 | heart failure | AstraZeneca | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05737940 | Apr 2023 → Jul 2025 | heart failure, pulmonary hypertension | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD3427 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04630067 ↗ |
| Action | Activate | “Novel Relaxin Receptor RXFP1 Agonist AZD3427 in the Treatment of Heart Failure:” PMID 39056338 ↗ Jul 2024 |
| Route | Subcutaneous | “by subcutaneous injection” PMID 39056338 ↗ Jul 2024 |
| Target | RXFP1 | “Novel Relaxin Receptor RXFP1 Agonist AZD3427 in the Treatment of Heart Failure:” PMID 39056338 ↗ Jul 2024 |